Studies have shown that hyperglycemia plays a deleterious role in the overproduction of IL-6, which is associated with increased lung infiltration and severity of COVID-19, for elevated IL-6, anti-IL-6 therapeutic strategies (Tocilizumab or Janus kinase inhibitors) may be particularly effective in DM patients with severe COVID-19 (12, 20). The gene discussed is IL6; the disease is COVID-19.